Editas Medicine (NQ: EDIT )
10.52 +0.27 (+2.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2023 Add to My Watchlist
All News about Editas Medicine
BMO Initiates Coverage On This Gene Editing Spearhead
June 17, 2022
Editas Medicine (NASDAQ:EDIT) will host a conference call at 08:00 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Editas Medicine (EDIT) Conference Call Follow this link to...
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
April 26, 2022
The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia from leading...
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following